Tissue Regenix Group plc
Company Profile
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.
Latest Company Summary
Investor Access
Daniel Lee, Chief Executive Officer, and Jay LeCoque, Executive Chairman, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 16:00 BST on Thursday 18 September. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
| Event | Date |
| Year End | 31 December |
| Half Year End | 30 June |
| Preliminary Results* | June |
| Interim Results | 18 September |
| AGM* | June |
* Months based on previous announcements of this kind
